Indian pharmaceutical companies Sun Pharmaceutical Industries and Cipla have issued recalls for specific products in the US market due to manufacturing-related concerns, as reported by the US Food and Drug Administration (USFDA). Sun Pharma’s US-based division, located in Princeton, New Jersey, is recalling over 26,000 bottles of a generic medication designed to address dandruff and skin conditions causing inflammation and itching, after failing impurity and degradation standards. The recall, classified as Class III by the USFDA, indicates that the product’s use is unlikely to result in adverse health effects.
In a separate instance, Sun Pharma is also recalling batches of Clindamycin Phosphate USP, a medication used for treating acne vulgaris, following findings of impurity levels and assay values beyond acceptable limits. This recall, also categorized as Class III, was initiated on November 26, 2025. Additionally, Cipla’s US arm, headquartered in Warren, New Jersey, is recalling more than 15,000 pre-filled syringes of Lanreotide Injection due to the presence of particulate matter. The USFDA has designated this recall as Class II, indicating that while the product may cause temporary or medically reversible health effects, the risk of severe harm is low.
The pharmaceutical market in the US, being the largest globally, places significant emphasis on regulatory compliance and product quality, underscoring the importance for drug manufacturers operating within the country to adhere to stringent standards.
